• Je něco špatně v tomto záznamu ?

Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement

M. Banach, T. Stulc, R. Dent, PP. Toth,

. 2016 ; 225 (-) : 184-196. [pub] 20160926

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18017001

Although statin therapy has proven to be the cornerstone for prevention and treatment of cardiovascular disease (CVD), there are many patients for whom long-term therapy remains suboptimal. The aims of this article are to review the current complex issues associated with statin use and to explore when novel treatment approaches should be considered. Statin discontinuation as well as adherence to statin therapy remain two of the greatest challenges for lipidologists. Evidence suggests that between 40 and 75% of patients discontinue their statin therapy within one year after initiation. Furthermore, whilst the reasons for persistence with statin therapy are complex, evidence shows that low-adherence to statins negatively impacts clinical outcomes and residual CV risk remains a major concern. Non-adherence or lack of persistence with long-term statin therapy in real-life may be the main cause of inadequate low density lipoprotein cholesterol lowering with statins. There is a large need for the improvement of the use of statins, which have good safety profiles and are inexpensive. On the other hand, in a non-cost-constrained environment, proprotein convertase subtilisin/kexin type 9 inhibitors should arguably be used more often in those patients in whom treatment with statins remains unsatisfactory.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017001
003      
CZ-PrNML
005      
20180515103330.0
007      
ta
008      
180515s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijcard.2016.09.075 $2 doi
035    __
$a (PubMed)27728862
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Banach, Maciej $u Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland; Healthy Aging Research Centre, Medical University of Lodz, Lodz, Poland; Polish Mother's Memorial Hospital Research Institute, Lodz, Poland. Electronic address: maciejbanach@aol.co.uk.
245    10
$a Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement / $c M. Banach, T. Stulc, R. Dent, PP. Toth,
520    9_
$a Although statin therapy has proven to be the cornerstone for prevention and treatment of cardiovascular disease (CVD), there are many patients for whom long-term therapy remains suboptimal. The aims of this article are to review the current complex issues associated with statin use and to explore when novel treatment approaches should be considered. Statin discontinuation as well as adherence to statin therapy remain two of the greatest challenges for lipidologists. Evidence suggests that between 40 and 75% of patients discontinue their statin therapy within one year after initiation. Furthermore, whilst the reasons for persistence with statin therapy are complex, evidence shows that low-adherence to statins negatively impacts clinical outcomes and residual CV risk remains a major concern. Non-adherence or lack of persistence with long-term statin therapy in real-life may be the main cause of inadequate low density lipoprotein cholesterol lowering with statins. There is a large need for the improvement of the use of statins, which have good safety profiles and are inexpensive. On the other hand, in a non-cost-constrained environment, proprotein convertase subtilisin/kexin type 9 inhibitors should arguably be used more often in those patients in whom treatment with statins remains unsatisfactory.
650    _2
$a kardiovaskulární nemoci $x krev $x farmakoterapie $7 D002318
650    _2
$a HDL-cholesterol $x antagonisté a inhibitory $x krev $7 D008076
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x škodlivé účinky $x terapeutické užití $7 D019161
650    _2
$a hypercholesterolemie $x krev $x farmakoterapie $7 D006937
650    12
$a adherence k farmakoterapii $7 D055118
650    _2
$a myalgie $x chemicky indukované $7 D063806
650    _2
$a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
650    _2
$a randomizované kontrolované studie jako téma $x metody $7 D016032
650    _2
$a rizikové faktory $7 D012307
650    _2
$a poruchy spánku a bdění $x chemicky indukované $7 D012893
650    _2
$a PCSK9 inhibitory $7 D000091362
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Stulc, Tomas $u 3rd Department of Internal Medicine, 1st University of Medicine, Prague, Czech Republic.
700    1_
$a Dent, Ricardo $u Amgen (Europe) GmbH, Zug, Switzerland.
700    1_
$a Toth, Peter P $u CGH Medical Center, Sterling, IL, USA; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
773    0_
$w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 225, č. - (2016), s. 184-196
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27728862 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103504 $b ABA008
999    __
$a ok $b bmc $g 1300625 $s 1013841
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 225 $c - $d 184-196 $e 20160926 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace